RxDoctor Payments Data

Roohi Katyal, MD

Epilepsy · Shreveport, LANPI 1871944074

Payments from drug & device makers

$31,904in general payments, 2019–2025

Across 112 payments — averaging $284.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$30K
  • UCB, Inc.$546
  • Novartis$247
  • Jazz Pharmaceuticals Inc.$172
  • Neurelis, Inc.$159
  • Argenx US, Inc.$144
  • plus $848 from 19 others

What the payments were for

  • Food & beverage$2,333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few epilepsy providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$30,848
Medicare patients
139
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate95$119,617
ValtocoDiazepam20$47,086
BriviactBrivaracetam17$24,305
Keppra XrLevetiracetam17$18,526
Lacosamide128$14,902
Levetiracetam367$11,993
Oxcarbazepine123$6,634
Carbamazepine ErCarbamazepine34$4,954
Lamotrigine ErLamotrigine47$4,157
Lamotrigine151$1,932
Divalproex Sodium64$1,759
Levetiracetam ErLevetiracetam39$1,711
Divalproex Sodium ErDivalproex Sodium54$1,523
Zonisamide77$1,487
Phenobarbital41$1,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$29,788$119,61795 claims
Neurelis, Inc.Valtoco$159$47,08620 claims
UCB, Inc.Briviact$546$24,30517 claims
Upsher-smith Laboratories LLCTopiramate$28$944127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other epilepsy in Shreveport

Where these figures come from

Is this you, or does something look wrong? →